AzTrials
AzTrials

Solid Tumor CancerPhase 1/2NCT07441174

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 study testing IN10018 in combination with RNK08954 in people with Solid Tumor Cancer and PDAC, run by InxMed (Shanghai) Co., Ltd. at 14 sites in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Solid Tumor Cancer, PDAC
What is being tested?
IN10018 in combination with RNK08954
Could I receive a placebo?
No, everyone receives an active treatment
How many people
92 participants
Where
14 sitesChina
Study dates
28 Feb 2026to 28 Feb 2031
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1. Voluntarily participate in the study after being fully informed, sign the written ICF, and agree to comply with the procedures specified in the protocol.
  • 2. Male or female aged ≥18 years at the time of signing the ICF.
  • 3. Subjects with pathologically confirmed locally advanced or metastatic solid tumors.
  • 4. Subjects confirmed to be KRASG12D mutation-positive in tumor tissue samples. Subjects may use historical results from local laboratories (within 2 years before signing the ICF).
  • Note: Test results must be provided by a laboratory certified by the Clinical Laboratory Improvement Amendments (CLIA) or an equivalent certification, a third-party laboratory recognized by the investigator, or the pathology department of grade A tertiary hospital.
  • 5. Requirements for tumor type are as follows:
Show all 23Show fewer
  • Phase Ib: Subjects with locally advanced or metastatic solid tumors who have documented radiologically disease progression, and are intolerant to standard treatment, or have no standard treatment, or have failed to standard treatment.
  • Phase II Cohort 1: Subjects with locally advanced or metastatic PDAC who have previously received gemcitabine- or nab-paclitaxel-based chemotherapy regimens or FOLFIRINOX/mFOLFIRINOX standard treatment and failed to standard treatment (have received at least first-line standard therapy and failed to standard treatment);
  • Phase II Cohort 2: Subjects with locally advanced or metastatic solid tumors who have documented radiologically disease progression and are intolerant to standard treatment, or have no standard treatment, or have failed to standard treatment (Selected tumor types will be determined based on prior study results).
  • 6. Presence of at least 1 measurable lesion assessable by computed - tomography (CT) or magnetic resonance imaging (MRI) according to RECIST Version 1.1. For lesions previously treated with radiotherapy or other local treatments, radiological confirmation of disease progression is required before they can be considered measurable lesions.
  • 7. ECOG performance status score of 0 or 1.
  • 8. Life expectancy of at least 3 months (assessed by the investigator).
  • 9. Laboratory tests within 7 days before the first dose confirm adequate bone marrow, liver, kidney, and coagulation function reserves, and no blood transfusion or blood products have been received within 14 days before the relevant tests:
  • Platelets ≥100×10⁹/L, and no platelet transfusion or thrombopoietin (TPO) treatment has been received within 14 days before the screening blood routine test.
  • Hemoglobin ≥90 g/L, and no blood transfusion, red blood cell transfusion, or erythropoietin (EPO) treatment has been received within 14 days before the screening blood routine test.
  • Neutrophil count ≥1.5×10⁹/L, and no colony-stimulating factor (CSF) has been used within 14 days before the screening blood routine test.
  • Creatinine clearance (Clcr) estimated by the Cockcroft-Gault (C-G) formula ≥60 mL/min, or estimated glomerular filtration rate (eGFR) estimated by the Modification of Diet in Renal Disease (MDRD) equation ≥60 mL/min.
  • Urine protein negative or weakly positive (±); or urine protein 1+, but urine protein-to-creatinine ratio (UPCR) in random morning urine <0.5 or 24-hour urine protein quantification <0.5 g/24 h.
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×Upper Limit of Normal (ULN) (≤5×ULN if liver metastasis exists). g) Total bilirubin ≤1.5×ULN (≤3×ULN is allowed for subjects with Gilbert's syndrome).
  • Prothrombin time and activated partial thromboplastin time ≤1.5×ULN, International Normalized Ratio (INR) ≤1.5. For subjects receiving anticoagulant therapy, INR <3.0 or within the target range of anticoagulant therapy (if applicable).
  • 10. Female subjects of childbearing potential must agree to abstain from sexual intercourse or use effective contraceptive methods from the time of signing the ICF until 6 months after the last dose of study drug. Acceptable contraceptive methods include: oral, injectable, or implantable hormonal contraception; intrauterine device or intrauterine system; male condom with spermicide or occlusive cap (diaphragm or cervical/vaginal cap).
  • 11. Male subjects must agree to abstain from sexual intercourse, undergo sterilization surgery, or use effective contraceptive methods from the time of signing the ICF until 6 months after the last dose of study drug.
  • Note: Effective contraceptive methods include: use of a male condom, with the female partner also using hormonal contraception or an intrauterine device (used for at least 4 weeks before administration); use of a male condom, with the female partner also using a diaphragm with spermicide or a cervical/vaginal cap.

Who cannot join

  • 1. Previous treatment with KRASG12D inhibitors. Note: Except for subjects in Phase Ib, who may have received previous treatment with KRASG12D inhibitors.
  • 2. Previous treatment with focal adhesion kinase (FAK) inhibitors.
  • 3. Received any anti-cancer drug treatment (including cytotoxic therapy, targeted therapy, biological therapy, or hormonal therapy other than alternative therapy) or other investigational drug treatment and radiotherapy within 14 days before the first dose.
  • 4. Have other KRAS mutations (excluding KRASG12D mutation), and have other positive mutation sites with available marketed targeted drugs.
  • 5. Subjects with known spinal cord compression symptoms, unstable or symptomatic/progressive central nervous system (CNS) metastasis, or meningeal metastasis. Subjects with a history of brain metastasis who are clinically and radiologically stable (i.e., no progression of CNS disease confirmed by two consecutive brain MRI or CT scans (if MRI is not suitable) with an interval of at least 4 weeks) may be enrolled (if the subject has previously received radiotherapy for brain metastasis, the MRI or CT scan must be performed at least 4 weeks after the last brain radiotherapy). For subjects who have received corticosteroid treatment, corticosteroids must have been discontinued for at least 2 weeks before the first dose of study drug. For subjects receiving anti-epileptic treatment, their medication dose must have been stable for at least 2 weeks.
  • 6. Any of the following cardiovascular conditions:
Show all 33Show fewer
  • Congestive heart failure with New York Heart Association (NYHA) functional class II or higher.
  • Severe arrhythmia and left bundle branch block requiring drug treatment.
  • Acute myocardial infarction, severe or unstable angina pectoris, coronary or peripheral artery bypass surgery within 6 months before the first dose.
  • Left ventricular ejection fraction (LVEF) <50%.
  • Prolonged corrected QT interval (QTcF) by Fridericia's formula at rest, with an average QTc interval >480 ms measured by three consecutive ECGs, or risk factors for torsades de pointes, such as clinically significant hypokalemia, family history of long QT syndrome, or familial arrhythmia (e.g., Pre-excitation Syndrome) as judged by the investigator.
  • Uncontrolled hypertension (defined as systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg after standardized antihypertensive drug treatment).
  • Deep vein thrombosis (other than implantable venous access port or catheter-related thrombosis) or pulmonary embolism within 6 months prior to the first dose of study treatment.
  • 7. Subjects with stroke or other severe cerebrovascular diseases (e.g., acute cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage) within 12 months prior to the first dose of study treatment.
  • 8. Subjects with interstitial lung disease or any active infection requiring systemic treatment within 14 days prior to the first dose of study treatment, including but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  • 9. Subjects with active autoimmune diseases (e.g., autoimmune thyroid disease, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease) requiring systemic treatment (including disease-modifying drugs, corticosteroids, or immunosuppressants) within the past 2 years. Hashimoto's thyroiditis, vitiligo, and psoriasis that do not require systemic treatment are excluded. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) is permitted.
  • 10.The investigator judges that the subject has a history or evidence of substance abuse, or has medical, psychological, or social conditions that may interfere with study participation or evaluation of study results.
  • Note: The following conditions are not recommended for enrollment, including but not limited to: 1) Presence of pleural effusion, pericardial effusion, or ascites that is poorly controlled and requires clinical management; 2) Active bleeding such as hemoptysis or gastrointestinal bleeding during the screening period, subjects with only a small amount of blood in sputum are allowed to enroll; 3) Received live vaccines or attenuated live vaccines within 28 days prior to the first dose of study treatment.
  • 11.Subjects with gastrointestinal (GI) disorders that may significantly impair the oral administration, absorption, or metabolism of the study drug, including dysphagia, refractory nausea and vomiting, malabsorption syndrome, gastrectomy or small bowel resection that impairs the oral absorption or metabolism of the study drug, symptomatic inflammatory bowel disease, and partial or complete intestinal obstruction.
  • Note: Subjects with clinical or radiological evidence of intestinal obstruction, or those who developed intestinal obstruction within the previous 3 months with unresolved underlying cause are not recommended for enrollment.
  • 12.The subject has not recovered from the toxicity of previous anti-tumor treatment (except for alopecia and pigmentation), defined as not recovered to NCI CTCAE v5.0 ≤Grade 1 (≤Grade 2 for peripheral neuropathy).
  • 13.The subject has undergone major surgery within 4 weeks prior to the first dose of study drug or has not fully recovered from previous surgical treatment. For percutaneous liver biopsy and other needle biopsies, a 14-day washout period is required before the first dose of study treatment.
  • Note: Subjects expected to undergo major surgery or those who need to interrupt study medication for scheduled surgery during the study treatment, should also be excluded.
  • 14.The subject has received or plans to receive within 2 weeks before the first dose of study drug treatment:
  • Drugs that are known to be narrow therapeutic window substrates of CYP3A.
  • Drugs that are known to be strong inducers or inhibitors of CYP3A4.
  • Drugs that are known to be strong inhibitors of P-glycoprotein.
  • Drugs known/potentially causing QTc interval prolongation or torsades de pointes (e.g., antiarrhythmic drugs).
  • Note: For details, refer to Appendix 9 in Section 10.9.
  • 15.Pregnant or lactating women.
  • 16.Positive for hepatitis B surface antigen (HBsAg) with hepatitis B virus deoxyribonucleic acid (HBV DNA) ≥2500 copies/mL or 500 IU/mL, positive for hepatitis C virus (HCV) antibody with HCV ribonucleic acid (HCV RNA) above the lower limit of detection, or positive for human immunodeficiency virus (HIV) antibody.
  • 17.A history of other malignant tumors within 5 years before the first dose, except for cured basal cell carcinoma of the skin, carcinoma in situ (e.g., carcinoma in situ of the breast, squamous cell carcinoma in situ of the skin, cervical carcinoma in situ).
  • 18.Known allergy (such as life-threatening hypersensitivity reaction) or other intolerances to IN10018, RNK08954 or their pharmaceutical excipients; or subjects with severe allergic diathesis.

Trial locations and contacts

14 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Shangyu Chen, Bachelor contact

86+18752093074

shangyu.chen@inxmed.com

Lily LI, Bachelor contact

13911551669

lily.li@inxmed.com

14 sites in 1 country

China14 sites, 14 recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality

    Lin Yang, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan

    Zhengyang Liu, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian

    Jianwei Yang, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong

    Zhihua Li, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310005

    Hangzhou, Zhejiang

    Zhengbo Song, M.D., 86-13857153345, songzb@zjcc.org.cn

    Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong

    He Tian, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Yan Zhang, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, He

    Jun Yao, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University

    Nanjing, Jiangsu

    Juan Du, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu

    Kuirobg Jiang, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality

    Liwei Wang, M.D, 86+13761254228, lwwang2013@163.com

    Not yet recruiting

  • The First Affiliated Hospital of China Medical University

    Shengyang, Liaoning

    Funan LIU, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang

    Gang Chen, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi

    Yinying Wu, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan

    Feng Wang, M.D, 86+18752093074, shangyu.chen@inxmed.com

    Not yet recruiting

Other trials in China

About this study

Official title: A Multicenter, Open-Label, Phase Ib/II Clinical Trial of IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

This is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage.

Read the detailed description

This is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage. Phase Ib - Dose Exploration Stage: It is designed to evaluate the safety and preliminary efficacy of IN10018 in combination with RNK08954 for the treatment of KRASG12D mutation-positive locally advanced or metastatic solid tumors, and to determine the Recommended Phase 2 Dose (RP2D) of the combination therapy. Phase II - Efficacy Exploration and Determination Stage: It will further evaluate the anti-tumor efficacy, safety, and pharmacokinetic (PK) characteristics of IN10018 in combination with RNK08954 in KRASG12D mutation-positive locally advanced or metastatic solid tumor (Pancreatic ductal adenocarcinoma (PDAC) shall be prioritized for enrollment). Based on the preliminary efficacy and safety data, one or two advanced solid tumor indications, including but not limited to PDAC, NSCLC, and CRC will be selected for adoption of a factorial or other appropriate study design and determination of sample size. Discussions with Center for Drug Evaluation (CDE) shall be completed prior to initiating the registrational study.

Being tested
IN10018 in combination with RNK08954
Keywords
KRASG12D mutation-positive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IN10018 in combination with RNK08954Drug

    Based on existing clinical data, the RP2D of IN10018 as monotherapy and in combination with chemotherapy, targeted therapy, and immunotherapy is 100 mg QD. For RNK08954 as monotherapy, the Maximum Tolerated Dose (MTD) was not reached during the dose escalation of the Phase I study, and effective doses with observed tumor responses were 800 mg QD, 1000 mg QD, and 1200 mg QD.

Study groups in NCT07441174
Study groupRoleWhat they receive
IN10018 in combination with RNK08954OtherIN10018 100mg QD PO + RNK08954 1000mg/1200mg QD PO Subject should take study drug till PD.
Receives: Drug: IN10018 in combination with RNK08954

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phase Ib:Recommended phase II dose (RP2D) of IN10018 in combination with RNK08954

    Determine the Recommended Phase 2 Dose (RP2D) of IN10018 in combination with RNK08954 in subjects with KRAS G12D mutation-positive locally advanced or metastatic solid tumors by evaluating up to 18 subjects with dose-limited toxicities (DLTs).

    Measured: Approximately 6 months

  2. Phase II: To evaluate the rate of Objective Response Rate (ORR) of IN10018 in combination with RNK08954 in subjects with KRASG12D mutation-positive locally advanced or metastatic solid tumors.

    Defined as the proportion of subjects with complete response (CR) or partial response (PR).

    Measured: Approximately 5 years

Secondary outcomes (6)

  1. To evaluate the rate of Objective Response Rate (ORR) of IN10018 in combination with RNK08954 in subjects with KRASG12D mutation-positive locally advanced or metastatic solid tumors.

    ORR：Defined as the proportion of subjects with complete response (CR) or partial response (PR).

    Measured: Approximately 5 years

  2. To evaluate the time of Duration of Response (DoR) of IN10018 in combination with RNK08954 in subjects with KRASG12D mutation-positive locally advanced or metastatic solid tumors.

    DoR：Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.

    Measured: Approximately 5 years

  3. To evaluate the rate of Disease Control Rate (DCR) of IN10018 in combination with RNK08954 in subjects with KRASG12D mutation-positive locally advanced or metastatic solid tumors.

    DCR：Defined as the proportion of patients with CR, PR, or stable disease (SD).

    Measured: Approximately 5 years

  4. To evaluate the duration of Progression-free Survival (PFS) of IN10018 in combination with RNK08954 in subjects with KRASG12D mutation-positive locally advanced or metastatic solid tumors.

    Defined as the time from the first dose of study treatment to first documentation of disease progression or to death due to any cause, whichever comes first.

    Measured: Approximately 5 years

  5. To Evaluate the duration of Overall survival (OS) of IN10018 in combination with RNK08954 in subjects with KRASG12D mutation-positive locally advanced or metastatic solid tumors.

    Defined as the time from the first dose of study treatment to the date of death due to any cause.

    Measured: Approximately 5 years

  6. To collect number of subjects with adverse event during the study.

    The adverse event include but not limited to abnormal lab report which investigator consider clinical significant, any suffering, pain, accident event during the study.

    Measured: Approximately 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Feb 2026
  2. Study start28 Feb 2026 (estimated)
  3. Primary completion28 Feb 2031 (estimated)
  4. Study completion28 Feb 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
92 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07441174
Sponsor's protocol ID
IN10018-026/RNK08954-02
Status last verified
Feb 2026
First submitted
13 Feb 2026
Last updated
27 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing IN10018 in combination with RNK08954 in people with Solid Tumor Cancer and PDAC, run by InxMed (Shanghai) Co., Ltd. at 14 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 33 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 14 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Shangyu Chen, Bachelor (86+18752093074, shangyu.chen@inxmed.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Phase Ib:Recommended phase II dose (RP2D) of IN10018 in combination with RNK08954 (time frame: Approximately 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07441174.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in